Pediatric multiple sclerosis (MS) may represent up to 10% of all MS cases. Establishing the diagnosis of MS in a child is complicated by the limited diagnostic criteria and the possibility of significant overlap with acute disseminated encephalomyelitis.
Can new chemical therapies improve the management of multiple sclerosis in children?
D'Amico E;Zanghì A;PATTI, Francesco
2017-01-01
Abstract
Pediatric multiple sclerosis (MS) may represent up to 10% of all MS cases. Establishing the diagnosis of MS in a child is complicated by the limited diagnostic criteria and the possibility of significant overlap with acute disseminated encephalomyelitis.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
Expert Opinion Pharmacoth. 2017.pdf
solo gestori archivio
Descrizione: Articolo principale
Tipologia:
Versione Editoriale (PDF)
Dimensione
6.8 MB
Formato
Adobe PDF
|
6.8 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.